Low-Dose Adjuvant Aspirin Decreases Incidence of Recurrence Among Patients with Resected PI3K-Altered CRC By Ogkologos - September 30, 2025 57 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ALASCCA study Source RELATED ARTICLESMORE FROM AUTHOR Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated Patients with Mantle Cell Lymphoma EMA Recommends a Change to the Terms of the Marketing Authorisation for Mosunetuzumab Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in Patients with mCSPC Harbouring BRCA1/2 or Other HRR Gene Alterations MOST POPULAR Few People with Cancer Undergo Testing for Inherited Gene Mutations August 1, 2023 Young Woman’s Breast Cancer Diagnosis Ends Up Saving Her Mom’s Life... September 27, 2021 EMA Recommends Granting a Marketing Authorisation for Elinzanetant September 26, 2025 Bagel Shop Owner Shaves Head To Support 10-Year-Old Customer October 27, 2021 Load more HOT NEWS EMA Recommends Extension of Indications for Enzalutamide Inavolisib Plus Palbociclib–Fulvestrant Prolongs PFS in Patients with PIK3CA-mutated, HR-positive, HER2-negative... Efficacy of Sintilimab in the Adjuvant Treatment for Patients with Resected,... EMA Recommends Granting a Marketing Authorisation for Nivolumab / Relatlimab